Troubled CytoDyn ditches COVID-19 indication, enters
tricky NASH landscape with new leader at helm
Like many biotechs amid the prolonged bear market, CytoDyn is axing some of its lead programs and trimming down its pipeline. The company's job may be harder than most, however, as it faces an ongoing clinical hold and has decided to focus its efforts on the tricky indication of nonalcoholic steatohepatitis (NASH).
No comments:
Post a Comment